90 related articles for article (PubMed ID: 38528593)
1. Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare
van Kuilenburg ABP; Pleunis-van Empel MCH; Brouwer RB; Sijben AEJ; Knapen DG; Oude Munnink TH; van Zanden JJ; Janssens-Puister J; Dobritzsch D; Meinsma R; Meijer-Jansen J; van Dooren SJM; Vijzelaar R; Pop A; Salomons GS; Maring JG; Niezen-Koning KE
JCO Precis Oncol; 2024 May; 8():e2300599. PubMed ID: 38709992
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Contribution of rs75017182 to Dihydropyrimidine Dehydrogenase mRNA Splicing and Enzyme Activity.
Nie Q; Shrestha S; Tapper EE; Trogstad-Isaacson CS; Bouchonville KJ; Lee AM; Wu R; Jerde CR; Wang Z; Kubica PA; Offer SM; Diasio RB
Clin Pharmacol Ther; 2017 Oct; 102(4):662-670. PubMed ID: 28295243
[TBL] [Abstract][Full Text] [Related]
3. Histone H3K27 Trimethylation Modulates 5-Fluorouracil Resistance by Inhibiting PU.1 Binding to the DPYD Promoter.
Wu R; Nie Q; Tapper EE; Jerde CR; Dunlap GS; Shrestha S; Elraiyah TA; Offer SM; Diasio RB
Cancer Res; 2016 Nov; 76(21):6362-6373. PubMed ID: 27578004
[TBL] [Abstract][Full Text] [Related]
4. A fatal case of 5-FU toxicity despite dose adjustment in a patient with a partial DPD deficiency receiving the FLOT regimen.
Zaanan A; Pallet N; Narjoz C; Loriot MA; Hafliger É
Eur J Cancer; 2024 Jul; 205():114102. PubMed ID: 38723381
[No Abstract] [Full Text] [Related]
5. Commentary: The pharmacogenomic landscape of an Indigenous Australian population.
White C; Paul C; Scott RJ; Ackland S
Front Pharmacol; 2024; 15():1373056. PubMed ID: 38813104
[No Abstract] [Full Text] [Related]
6. Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency.
Etienne-Grimaldi MC; Pallet N; Boige V; Ciccolini J; Chouchana L; Barin-Le Guellec C; Zaanan A; Narjoz C; Taieb J; Thomas F; Loriot MA;
Eur J Cancer; 2023 Mar; 181():3-17. PubMed ID: 36621118
[TBL] [Abstract][Full Text] [Related]
7. A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report.
Malekkou A; Tomazou M; Mavrikiou G; Dionysiou M; Georgiou T; Papaevripidou I; Alexandrou A; Sismani C; Drousiotou A; Grafakou O; Petrou PP
BMC Med Genomics; 2024 Mar; 17(1):78. PubMed ID: 38528593
[TBL] [Abstract][Full Text] [Related]
8. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC
Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938
[TBL] [Abstract][Full Text] [Related]
9. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
10. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
[TBL] [Abstract][Full Text] [Related]
11. New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine.
García-González X; Kaczmarczyk B; Abarca-Zabalía J; Thomas F; García-Alfonso P; Robles L; Pachón V; Vaz Á; Salvador-Martín S; Sanjurjo-Sáez M; López-Fernández LA
Cancer Chemother Pharmacol; 2020 Jul; 86(1):45-54. PubMed ID: 32529295
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP
Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491
[TBL] [Abstract][Full Text] [Related]
13. Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients:
Ragia G; Maslarinou A; Atzemian N; Biziota E; Koukaki T; Ioannou C; Balgkouranidou I; Kolios G; Kakolyris S; Xenidis N; Amarantidis K; Manolopoulos VG
Front Pharmacol; 2023; 14():1248898. PubMed ID: 37781702
[No Abstract] [Full Text] [Related]
14. Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe.
de With M; Sadlon A; Cecchin E; Haufroid V; Thomas F; Joerger M; van Schaik RHN; Mathijssen RHJ; Largiadèr CR;
ESMO Open; 2023 Apr; 8(2):101197. PubMed ID: 36989883
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
